Greater Tulsa Reporter
CTCA's stem cell transplant unit’s new leader, Dr. Lynch. Pictured with Lynch is Glinda Huitt, RN, BSN, OCN, who is director of inpatient services and oversees the stem cell transplant unit.
Cancer Treatment Centers of America in Tulsa (CTCA) announces the addition of Joseph P. Lynch, MD, MS as medical director of the hospital’s new stem cell transplant and cell therapy program. The CTCA stem cell transplant unit is expected to open in early March and will be the third in the state.
Through this new service offered at the Tulsa hospital, patients with malignant blood cancers will now be able to complete treatment through bone marrow transplant on-site while keeping their continuity of care with CTCA. This service will be available to patients with hematology malignancies such as chronic and acute leukemia, Hodgkin’s and Non-Hodgkin’s lymphoma, multiple myeloma, and any other malignant blood cancers.
Dr. Lynch is board certified in oncology and internal medicine and has been performing bone marrow transplants since 1985. Board certified in medical oncology and internal medicine, he earned a medical degree from Georgetown University School of Medicine in Washington, D.C. Before pursuing a medical degree, he received a master’s degree in physiology and biophysics from Georgetown University and a bachelor’s degree in biologic sciences from St. John’s University in Queens, New York.
Dr. Lynch completed an internship at Cleveland Clinic, an internal medicine residency at West Virginia University in Morgantown and a medical oncology fellowship at Allegheny General Hospital in Pittsburgh, Pennsylvania. Additionally, he completed a bone marrow transplantation fellowship at the University of Louisville in Kentucky and served as a visiting fellow in the bone marrow transplantation program at the Fred Hutchinson Cancer Research Center in Seattle.
In addition to caring for patients at hospitals in Tulsa and Morgantown, West Virginia for a number of years, Dr. Lynch was the founding Director of the Bone Marrow Transplantation Program at West Virginia University. While there, he was also an associate professor of medicine. He also has served as clinical associate professor at the University of Oklahoma Center for Health Sciences in Tulsa.
Dr. Lynch has conducted clinical research on multiple hematologic malignancies as it relates to blood and marrow transplantation. His work has been published in The New England Journal of Medicine, Bone Marrow Transplantation, Leukemia and Lymphoma and other clinical publications.
Dr. Lynch is a member of several professional associations, including the American Society of Clinical Oncology, American Society for Blood and Marrow Transplantation and the American Society of Hematology. He is a president of the Oklahoma Society of Clinical Oncology. He serves on the national board of the Community Oncology Alliance and is a certified inspector for the Foundation for the Accreditation of Cellular Therapy.
“With the addition of a remarkable physician like Dr. Lynch, our patients will no longer have to travel off-site for bone marrow transplantation and peripheral blood stem cell transplantation,” said Steve Mackin, CTCA president and CEO in Tulsa. “We are excited about offering our patients more options under one roof.”